Growth Hormone for Turner Syndrome (1997)
The FDA approved growth hormone treatment for Turner syndrome, a chromosomal condition causing short stature in girls. The approval established a precedent for pharmacological intervention in genetic growth disorders, though treatment required daily injections for years.
Treatment became standard of care for Turner syndrome, with most affected children receiving growth hormone therapy.
Demonstrated that chronic injection therapy could be successfully adopted in pediatric populations, paving the way for Voxzogo's approach two decades later.
Voxzogo's approval followed a similar regulatory path, and the Turner syndrome experience showed that families will accept daily injections for growth benefits—but also highlighted the opportunity for less burdensome alternatives.